|
|||||
|
|
Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines |
|
| Authors: | Joshua M. Cohen MD MPH FAHS David W. Dodick MD Ronghua Yang PhD Lawrence C. Newman MD Thomas Li PhD Ernesto Aycardi MD Marcelo E. Bigal MD PhD |
| Affiliation: | 1. Medical Affairs, Teva Pharmaceutical Industries, Frazer, PA, USA;2. Department of Neurology, Mayo Clinic, Phoenix, AZ, USA;3. Biostatistics, Teva Pharmaceutical Industries, Frazer, PA, USA;4. Department of Neurology, New York University Medical Center, New York, NY, USA;5. Clinical Development, Teva Pharmaceutical Industries, Frazer, PA, USA |
| Abstract: | |
| Keywords: | migraine fremanezumab TEV‐48125 calcitonin‐gene‐related peptide migraine preventive medication |